Anagrelide (Agrylin) is a thrombocytopenic agent primarily indicated for the treatment of thrombocythemia caused by myeloproliferative neoplasms.
Indications for Anagrelide (Agrylin)
Reducing Elevated Platelet Counts
This drug effectively reduces platelet production by inhibiting the maturation and differentiation of megakaryocytes.
Reducing the Risk of Thrombosis
Patients with thrombocythemia face a relatively high risk of thrombosis, which may lead to severe complications such as stroke, deep vein thrombosis, or myocardial infarction.
Anagrelide significantly lowers such risks by controlling platelet counts.
Improving Related Symptoms
This includes preventing and alleviating clinical symptoms like thrombotic bleeding events.
It is particularly important for patients with gestational thrombocythemia, a condition that increases the risks of miscarriage, stillbirth, preeclampsia, and other adverse outcomes.
Specifications and Properties of Anagrelide (Agrylin)
Dosage Form and Content
Anagrelide is available in capsule form, with each capsule containing 0.5 mg of anagrelide (equivalent to 0.61 mg of anagrelide hydrochloride USP).
The capsules are opaque white and imprinted with "063" in black.
Chemical Composition
Active Ingredient: 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one monohydrochloride monohydrate. Its molecular formula is C₁₀H₇Cl₂N₃O•HCl•H₂O, and its molecular weight is 310.55.
Excipients
The capsules also contain the following inactive ingredients: Lactose Anhydrous NF, Crospovidone NF, Lactose Monohydrate NF, Magnesium Stearate NF, Microcrystalline Cellulose NF, and Povidone NF.
The capsule shell is composed of gelatin, titanium dioxide, and black iron oxide.
Physicochemical Properties
Anagrelide hydrochloride is an off-white powder. It is very slightly soluble in water and slightly soluble in dimethyl sulfoxide (DMSO) and dimethylformamide (DMF).
Storage Methods for Anagrelide (Agrylin)
Temperature Control
It should be stored at room temperature below 25°C, avoiding exposure to high temperatures and freezing.
Extreme temperatures may affect the stability of the capsules and the efficacy of the drug.
Humidity Management
It must be kept in a dry environment to prevent the capsules from absorbing moisture and deteriorating.
The desiccant in the original packaging should not be removed prematurely.
Light Protection
Due to the risk of photosensitivity, direct sunlight should be avoided, and the drug should be stored in its original packaging for light protection.
Safe Storage
It must be stored out of the reach of children to prevent accidental ingestion.
Expired medications should be disposed of through professional channels and not discarded randomly.
Transportation Requirements
During transportation, severe vibration and extreme temperature changes should be avoided, and the integrity of the drug packaging must be ensured.


